Journal of Renal Nutrition
Volume 17, Issue 4 , Pages 235-242 , July 2007

Dietary Intake of Patients With Chronic Kidney Disease Entering the LORD Trial: Adjusting for Underreporting

  • Robert G. Fassett, MBBS

      Affiliations

    • School of Human Movement Studies, University of Queensland, Brisbane, Australia.
    • Renal Research Tasmania, Launceston General Hospital, Launceston, Tasmania, Australia.
    • ,
  • Iain K. Robertson, MPH

      Affiliations

    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia.
    • ,
  • Dominic P. Geraghty, PhD

      Affiliations

    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia.
    • ,
  • Madeleine J. Ball, MD

      Affiliations

    • School of Human Life Sciences, University of Tasmania, Launceston, Tasmania, Australia.
    • ,
  • Jeff S. Coombes, PhD

      Affiliations

    • School of Human Movement Studies, University of Queensland, Brisbane, Australia.
    • Corresponding Author InformationAddress reprint requests to Jeff S. Coombes, PhD, School of Human Movement Studies, Rm 535 Connell Building, University of Queensland, St. Lucia, Queensland, Australia 4072.

  • Image Result

    Nutrient intakes as a percentage of recommendations (mean 95% confidence interval). *Complex carbohydrates, fat, saturated fat, and cholesterol are DVs adjusted for EI using the K/DOQI recommendation

    Nutrient intakes as a percentage of recommendations (mean 95% confidence interval). *Complex carbohydrates, fat, saturated fat, and cholesterol are DVs adjusted for EI using the K/DOQI recommendation (125 kJ/d). Protein, fat, saturated fat, and cholesterol intakes are all recommended to be below the indicated 100%, thus the different shading. Box plots show 10th, 25th, 50th, 75th, and 90th percentiles. CHO, carbohydrate; DV, daily value; EI, energy intake; K/DOQI, National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

 This project was supported by a grant from the Clifford Craig Medical Research Trust, C. Prosser Green Trust. Pfizer Pharmaceuticals provided atorvastatin and placebo for the LORD trial.

PII: S1051-2276(07)00096-9

doi: 10.1053/j.jrn.2007.04.004

Journal of Renal Nutrition
Volume 17, Issue 4 , Pages 235-242 , July 2007

Article Tools

* Image Usage & Resolution